Intensive Pharmacokinetics of the Nelfinavir-Rifabutin Interaction in Patients With HIV-Related Tuberculosis Treated With a Rifabutin-Based Regimen
Sponsor: Centers for Disease Control and Prevention
Listed as NCT00018083, this NA trial focuses on HIV Infections and Tuberculosis and remains ongoing. Sponsored by Centers for Disease Control and Prevention, it has been updated 5 times since 2026, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Unknown NA
-
Jul 2024 — Sep 2024 [monthly]
Unknown NA
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status NA
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status NA
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Centers for Disease Control and Prevention
- National Center for Research Resources (NCRR)
For direct contact, visit the study record on ClinicalTrials.gov .